Diletta Fontana

610 total citations
19 papers, 186 citations indexed

About

Diletta Fontana is a scholar working on Pulmonary and Respiratory Medicine, Hematology and Molecular Biology. According to data from OpenAlex, Diletta Fontana has authored 19 papers receiving a total of 186 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Hematology and 5 papers in Molecular Biology. Recurrent topics in Diletta Fontana's work include Lung Cancer Treatments and Mutations (6 papers), Acute Myeloid Leukemia Research (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Diletta Fontana is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Acute Myeloid Leukemia Research (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Diletta Fontana collaborates with scholars based in Italy, France and Peru. Diletta Fontana's co-authors include Carlo Gambacorti‐Passerini, Luca Mologni, Monica Ceccon, Rocco Piazza, Alessandra Pirola, Giovanni De Giudici, Elena Maria Elli, Fabio Pagni, Marco Antoniotti and Fabrizio Angaroni and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Diletta Fontana

18 papers receiving 184 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Diletta Fontana Italy 7 96 88 82 34 26 19 186
Helen Marr United Kingdom 10 23 0.2× 64 0.7× 65 0.8× 31 0.9× 64 2.5× 18 188
Sumito Shingaki Japan 4 24 0.3× 87 1.0× 35 0.4× 11 0.3× 16 0.6× 15 134
Shrinidhi Nathany India 7 132 1.4× 73 0.8× 88 1.1× 18 0.5× 5 0.2× 53 196
Gareth Rivalland Australia 10 98 1.0× 78 0.9× 112 1.4× 12 0.4× 7 0.3× 26 248
Jee‐Soo Lee South Korea 6 30 0.3× 64 0.7× 62 0.8× 9 0.3× 12 0.5× 24 164
Roha Afzal United States 2 68 0.7× 193 2.2× 204 2.5× 33 1.0× 12 0.5× 2 327
Muriel Duluc France 6 35 0.4× 102 1.2× 147 1.8× 9 0.3× 28 1.1× 11 225
Jana Mihályová Czechia 7 17 0.2× 90 1.0× 136 1.7× 57 1.7× 49 1.9× 16 251
Constanze Schneider Germany 6 22 0.2× 92 1.0× 66 0.8× 14 0.4× 8 0.3× 21 172
Pedro Sánchez‐Godoy Spain 7 19 0.2× 99 1.1× 65 0.8× 100 2.9× 46 1.8× 18 220

Countries citing papers authored by Diletta Fontana

Since Specialization
Citations

This map shows the geographic impact of Diletta Fontana's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diletta Fontana with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diletta Fontana more than expected).

Fields of papers citing papers by Diletta Fontana

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diletta Fontana. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diletta Fontana. The network helps show where Diletta Fontana may publish in the future.

Co-authorship network of co-authors of Diletta Fontana

This figure shows the co-authorship network connecting the top 25 collaborators of Diletta Fontana. A scholar is included among the top collaborators of Diletta Fontana based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diletta Fontana. Diletta Fontana is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Sala, Elisa, Geeta G. Sharma, Maria Gemelli, et al.. (2024). New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients. npj Precision Oncology. 8(1). 29–29. 3 indexed citations
3.
Elli, Elena Maria, Mario Mauri, Diletta Fontana, et al.. (2024). Idiopathic erythrocytosis: a germline disease?. Clinical and Experimental Medicine. 24(1). 11–11. 3 indexed citations
4.
Fusella, Federica, Roberta Ferretti, Ugo Ala, et al.. (2024). miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia. Scientific Reports. 14(1). 15089–15089. 2 indexed citations
5.
6.
Fontana, Diletta, Fabrizio Angaroni, De Luca, et al.. (2023). Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients. Nature Communications. 14(1). 5982–5982. 2 indexed citations
7.
Fontana, Diletta, Elena Maria Elli, Fabio Pagni, & Rocco Piazza. (2023). Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review. Cancers. 15(12). 3175–3175. 10 indexed citations
8.
Ramazzotti, Daniele, Fabrizio Angaroni, Davide Maspero, et al.. (2022). Large-scale analysis of SARS-CoV-2 synonymous mutations reveals the adaptation to the human codon usage during the virus evolution. Virus Evolution. 8(1). veac026–veac026. 17 indexed citations
9.
Aroldi, Andrea, Lorenza Borin, Luisa Verga, et al.. (2022). Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706). SHILAP Revista de lepidopterología. 3(4). 1201–1208. 3 indexed citations
10.
Sharma, Geeta G., Mario Mauri, Diletta Fontana, et al.. (2021). Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma. Cancers. 13(17). 4422–4422. 10 indexed citations
11.
Fontana, Diletta, Carlo Gambacorti‐Passerini, & Rocco Piazza. (2021). Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia. Frontiers in Oncology. 11. 756348–756348. 6 indexed citations
12.
Fontana, Diletta, Carlo Gambacorti‐Passerini, & Rocco Piazza. (2021). Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage. Molecular & Cellular Oncology. 8(2). 1877598–1877598. 6 indexed citations
13.
Nucera, Silvia, Grazia Fazio, Rocco Piazza, et al.. (2020). Germ‐Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition. HemaSphere. 4(5). e460–e460. 2 indexed citations
14.
Fontana, Diletta, Monica Ceccon, Carlo Gambacorti‐Passerini, & Luca Mologni. (2015). Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALK. Cancer Medicine. 4(7). 953–965. 67 indexed citations
15.
Piazza, Rocco, Alessandra Pirola, Carla Donadoni, et al.. (2015). ETNK1 Is an Early Event and SETBP1 a Late Event in Atypical Chronic Myeloid Leukemia. Blood. 126(23). 3652–3652. 1 indexed citations
16.
Mologni, Luca, Monica Ceccon, Diletta Fontana, et al.. (2015). Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors. Cancer Research. 75(15_Supplement). 3583–3583. 1 indexed citations
17.
Ceccon, Monica, Luca Mologni, Giovanni De Giudici, et al.. (2014). Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma. Molecular Cancer Research. 13(4). 775–783. 47 indexed citations
18.
Arduino, Carlo, Marina Ferrone, Alfredo Brusco, et al.. (1998). Congenital bilateral absence of vas deferens with a new missense mutation (P499A) in the CFTR gene. Clinical Genetics. 53(3). 202–204. 4 indexed citations
19.
Fontana, Diletta, et al.. (1998). Tuberculosis epidemiology. Urologia Journal. 65(1). 151–154. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Helen Marr Breakdown of academic impact, for papers by Sumito Shingaki Breakdown of academic impact, for papers by Shrinidhi Nathany Breakdown of academic impact, for papers by Gareth Rivalland Breakdown of academic impact, for papers by Jee‐Soo Lee Breakdown of academic impact, for papers by Roha Afzal Breakdown of academic impact, for papers by Muriel Duluc Breakdown of academic impact, for papers by Jana Mihályová Breakdown of academic impact, for papers by Constanze Schneider Breakdown of academic impact, for papers by Pedro Sánchez‐Godoy
Rankless by CCL
2026